...
机译:DCC-2036的治疗活性是一种新型酪氨酸激酶抑制剂,通过靶向AXL / MET对抗三阴性乳腺癌患者衍生的异种移植物
Univ South China Inst Clin Med Affiliated Hosp 1 69 Chuanshan Rd Hengyang 421001 Hunan;
Tsinghua Univ Sch Med Dept Biol Beijing Peoples R China;
Univ South China Inst Clin Med Affiliated Hosp 1 69 Chuanshan Rd Hengyang 421001 Hunan;
Univ South China Affiliated Hosp 1 Dept Spine Surg Hengyang Hunan Peoples R China;
Univ South China Inst Clin Med Affiliated Hosp 1 69 Chuanshan Rd Hengyang 421001 Hunan;
Univ South China Affiliated Hosp 1 Dept Med Oncol Hengyang Hunan Peoples R China;
Univ South China Inst Clin Med Affiliated Hosp 1 69 Chuanshan Rd Hengyang 421001 Hunan;
Univ South China Affiliated Hosp 1 Dept Thyroid Breast Surg Hengyang Hunan Peoples R China;
Univ South China Affiliated Hosp 1 Dept Pathol Hengyang Hunan Peoples R China;
Univ South China Inst Clin Med Affiliated Hosp 1 69 Chuanshan Rd Hengyang 421001 Hunan;
Univ South China Inst Clin Med Affiliated Hosp 1 69 Chuanshan Rd Hengyang 421001 Hunan;
Univ South China Inst Pharm &
Pharmacol Hengyang Hunan Peoples R China;
Tsinghua Univ Guangdong Prov Key Lab Chem Biol Grad Sch Shenzhen Peoples R China;
Univ South China Inst Clin Med Affiliated Hosp 1 69 Chuanshan Rd Hengyang 421001 Hunan;
DCC-2036; AXL; MET; TNBC; PDX;
机译:DCC-2036的治疗活性是一种新型酪氨酸激酶抑制剂,通过靶向AXL / MET对抗三阴性乳腺癌患者衍生的异种移植物
机译:酪氨酸激酶抑制剂E-3810与紫杉醇联合抑制晚期三阴性乳腺癌异种移植物的生长
机译:AXL对于EGFR酪氨酸激酶抑制剂的EGFR酪氨酸激酶抑制剂的治疗效率至关重要,通过NFI在乳腺癌中
机译:通过平行反应监测抑制剂LC-MS的定量蛋白质组学分析,来自患者源乳癌异种移植物的富集激酶
机译:靶向蛋白质酪氨酸激酶的RNAi筛选可将布鲁顿酪氨酸激酶(BTK)识别为乳腺癌细胞生存因子。
机译:RON和达到共同过度表达是三重阴性乳腺癌中酪氨酸激酶抑制剂的差的存活率和治疗靶标的显着病理特征
机译:DCC-2036的治疗活性,一种新的酪氨酸激酶抑制剂,通过靶向AXL / MET对抗三阴性乳腺癌患者衍生的异种移植物
机译:TNK2酪氨酸激酶作为三阴性乳腺癌的新型治疗靶点。